Moonwalk Biosciences Raises $70M Series B for Adipose-Targeted RNAi
Moonwalk Biosciences raised an oversubscribed $70 million Series B to advance adipose-targeted RNAi medicines for obesity and cardiometabolic disease.
TL;DR: Moonwalk Biosciences announced an oversubscribed $70 million Series B on September 8, 2026, co-led by Alpha Wave and YK Bioventures.
Canonical company profile: Moonwalk Biosciences.
The round
Eli Lilly and Company, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures also participated.
The financing will advance Moonwalk's lead obesity program toward the clinic and expand its pipeline of adipose-selective RNAi medicines.
What Moonwalk is trying to do
Moonwalk is developing RNA interference therapies designed to act selectively in adipose tissue.
The company's obesity thesis is therefore different from simply developing another incretin or GLP-1 drug.
If adipose-selective gene silencing can reduce fat while preserving lean mass, it could address one of the concerns around rapid weight-loss therapies.
Why the Series B matters
The company launched with $57 million of financing in 2024. The new $70 million round brings significant additional capital as Moonwalk moves from platform work toward clinical development.
At this stage the most important milestones are not valuation headlines. They are:
- candidate selection;
- IND-enabling work;
- first-in-human entry;
- safety;
- durability of effect; and
- preservation of lean mass.
VCT classification
VCT records the September financing as a company-disclosed $70M Series B. No new valuation was disclosed with the round.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
